NASDAQ:PHIO

Phio Pharmaceuticals Stock Forecast, Price & News

$2.24

0.00 (0.00 %)

(As of 11/25/2020 12:00 AM ET)

Add

Compare

Today's Range

$2.23

Now: $2.24▼

$2.29

50-Day Range

$2.01

MA: $2.19▼

$2.48

52-Week Range

$1.60

Now: $2.24▼

$13.61

Volume236,983 shs

Average Volume663,419 shs

Market Capitalization$12.95 million

P/E RatioN/A

Dividend YieldN/A

Beta2.33

Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum MÃ¼nchen. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Phio Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, Phio Pharmaceuticals has a forecasted upside of 78.6% from its current price of $2.24.
Amount of Analyst Coverage
Phio Pharmaceuticals has received no research coverage in the past 90 days.

2.5 Community Rank

Outperform Votes
Phio Pharmaceuticals has received 30 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Phio Pharmaceuticals has received 30 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Phio Pharmaceuticals has received 50.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Phio Pharmaceuticals and other stocks. Vote “Outperform” if you believe PHIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PHIO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Phio Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Phio Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Phio Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.52% of the stock of Phio Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 2.26% of the stock of Phio Pharmaceuticals is held by institutions.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Phio Pharmaceuticals are expected to grow in the coming year, from ($2.23) to $0.29 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Phio Pharmaceuticals is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Phio Pharmaceuticals is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Phio Pharmaceuticals has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.45 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:PHIO

Previous Symbol

CUSIPN/A

CIKN/A

Webphiopharma.com

Phone508-767-3861

Employees11

Debt

Debt-to-Equity Ratio0.01

Current Ratio10.33

Quick Ratio10.33

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$20,000.00

Price / Sales647.47

Cash FlowN/A

Price / Cash FlowN/A

Book Value$8.59 per share

Price / Book0.26

Profitability

EPS (Most Recent Fiscal Year)($19.33)

Net Income$-8,910,000.00

Net MarginsN/A

Return on Equity-81.51%

Return on Assets-66.70%

Miscellaneous

Outstanding Shares5,781,000

Market Cap$12.95 million

Next Earnings Date3/25/2021 (Estimated)

OptionableNot Optionable

$2.24

0.00 (0.00 %)

(As of 11/25/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive PHIO News and Ratings via Email

Sign-up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter.

Phio Pharmaceuticals (NASDAQ:PHIO) Frequently Asked Questions

How has Phio Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Phio Pharmaceuticals' stock was trading at $2.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PHIO shares have decreased by 19.1% and is now trading at $2.24.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Phio Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phio Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Phio Pharmaceuticals.

What stocks does MarketBeat like better than Phio Pharmaceuticals?

Wall Street analysts have given Phio Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Phio Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Phio Pharmaceuticals' next earnings date?

Phio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 25th 2021.
View our earnings forecast for Phio Pharmaceuticals.

How were Phio Pharmaceuticals' earnings last quarter?

Phio Pharmaceuticals Corp (NASDAQ:PHIO) announced its quarterly earnings data on Sunday, November, 15th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.38) by $0.02.
View Phio Pharmaceuticals' earnings history.

What price target have analysts set for PHIO?

1 Wall Street analysts have issued 1 year target prices for Phio Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Phio Pharmaceuticals' stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 78.6% from the stock's current price.
View analysts' price targets for Phio Pharmaceuticals.

Are investors shorting Phio Pharmaceuticals?

Phio Pharmaceuticals saw a increase in short interest in October. As of October 30th, there was short interest totaling 87,000 shares, an increase of 564.1% from the October 15th total of 13,100 shares. Based on an average trading volume of 450,600 shares, the short-interest ratio is presently 0.2 days. Currently, 1.5% of the company's stock are short sold.
View Phio Pharmaceuticals' Short Interest.

Who are some of Phio Pharmaceuticals' key competitors?

Some companies that are related to Phio Pharmaceuticals include Vascular Biogenics (VBLT), PLx Pharma (PLXP), Conatus Pharmaceuticals (CNAT), Merrimack Pharmaceuticals (MACK), Daré Bioscience (DARE), Citius Pharmaceuticals (CTXR), Edesa Biotech (EDSA), Diffusion Pharmaceuticals (DFFN), Onconova Therapeutics (ONTX), Moleculin Biotech (MBRX), Anixa Biosciences (ANIX), Seelos Therapeutics (SEEL), BioLineRx (BLRX), Forward Pharma A/S (FWP) and CV Sciences (CVSI).
View all competitors.

What other stocks do shareholders of Phio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phio Pharmaceuticals investors own include DURECT (DRRX), CymaBay Therapeutics (CBAY), Ocugen (OCGN), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Boxlight (BOXL), Evofem Biosciences (EVFM), Fulcrum Therapeutics (FULC), Jaguar Health (JAGX) and Milestone Pharmaceuticals (MIST).

Who are Phio Pharmaceuticals' key executives?

Phio Pharmaceuticals' management team includes the following people:

Dr. Gerrit Dispersyn Ph.D., Dr. Med. Sc, Pres, CEO & Director (Age 45, Pay $541.72k)
Ms. Caitlin Kontulis, VP of Fin. & Admin. and Sec. (Age 34)

What is Phio Pharmaceuticals' stock symbol?

Phio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHIO."

Who are Phio Pharmaceuticals' major shareholders?

Phio Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include GSA Capital Partners LLP (0.37%).
View institutional ownership trends for Phio Pharmaceuticals.

Which major investors are buying Phio Pharmaceuticals stock?

PHIO stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP.
View insider buying and selling activity for Phio Pharmaceuticals.

How do I buy shares of Phio Pharmaceuticals?

Shares of PHIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Phio Pharmaceuticals' stock price today?

One share of PHIO stock can currently be purchased for approximately $2.24.

How big of a company is Phio Pharmaceuticals?

Phio Pharmaceuticals has a market capitalization of $12.95 million and generates $20,000.00 in revenue each year. The company earns $-8,910,000.00 in net income (profit) each year or ($19.33) on an earnings per share basis. Phio Pharmaceuticals employs 11 workers across the globe.

What is Phio Pharmaceuticals' official website?

The official website for Phio Pharmaceuticals is phiopharma.com.

How can I contact Phio Pharmaceuticals?

Phio Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The company can be reached via phone at 508-767-3861 or via email at [email protected]

This page was last updated on 11/27/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings